Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RGT.AU
- Price
- 0.08
- Stock movement down
- -0.00 (-2.60%)
- Company name
- Argent Biopharma Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 5.83M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -75.81%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-31
DIVIDENDS
RGT.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.08 |
| Daily high | 0.08 |
| Daily low | 0.07 |
| Daily Volume | 52K |
| All-time high | 3610.50 |
| 1y analyst estimate | 20.12 |
| Beta | 0.57 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Dec 2025 |
Downside potential
Loading...
Downside potential data
| RGT.AU | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.10% |
| Highest price drop | -100.00% | -19.00% |
| Date of highest drop | 13 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -100.00% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 270 days | 89 days |
COMPANY DETAILS
Marketcap
5.83M
Marketcap category
Small-cap
Description
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found